Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of **ulodesine**, a purine nucleoside phosphorylase inhibitor, and **allopurinol**, a xanthine oxidase inhibitor. This combination is being investigated for the treatment of **gout** and **hyperuricemia**, particularly in patients who are not adequately controlled with allopurinol monotherapy or who have moderate renal insufficiency. Ulodesine inhibits purine nucleoside phosphorylase, reducing production of uric acid upstream of xanthine oxidase, while allopurinol inhibits xanthine oxidase, further reducing uric acid production. Together, they aim to more effectively lower serum uric acid levels than either agent alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ulodesine + allopurinol.